Global Stem Cell Therapy Market

CAR-T Therapy Market Definition

The chimeric antigen receptor -T therapy market consists of sales of CAR-T therapy products and related services by entities (organizations, sole traders and partnerships) that develop chimeric antigen receptor (CAR) T-cell therapies to treat blood cancers. CAR-T therapy is type of immunotherapy in which T-cells taken from patient’s blood are modified in a laboratory with the addition of a special protein receptor that grants T-cells the power to recognize as well as kill cancer cells easily, along with infusing the same back into that patient. This special protein receptor, known as the chimeric antigen receptor (CAR), attaches to a specific protein on a patient’s cancer cells. The infused cells multiply and prevail in the patient’s body as living drugs. This industry includes establishments that are involved in the research and development to introduce new targeted cell therapies for treating indications related mostly to hematological malignancies. However, some of the pipeline CAR-T therapies are aimed at targeting solid tumors including pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, kidney cancer, brain tumor, and other cancer types.

The cell culture market consists of sales of cell culture equipment and consumables for drug development and related services. Cell culture is the process by which cells are grown in suitable sterile environments under controlled conditions. Cell culture is one of the major tools used in molecular & cellular biology, manufacturing of medicines, and large-scale manufacture of biological compounds.

The cell culture market covered in this report is segmented by type into primary cell culture, secondary cell culture, cell line. The cell culture market is also segmented by media into natural, artificial, and by applications into stem cell technologies, cancer research, biopharmaceutical, tissue engineering & regenerative medicine, others.

The global cell culture market is expected to grow from $15.13 billion in 2020 to $16.45 billion in 2021 at a compound annual growth rate (CAGR) of 8.7%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cell culture market is expected to reach $27.22 billion in 2025 at a CAGR of 13%.

The rise in the demand for cell therapy is expected to drive the cell culture market. In cell therapy, viable cells are injected or implanted into a patient's body to cure a medicinal disease. Cell culture is a vital step in any cell-based therapy. According to the Cancer Research Institute (CRI), there are about 1,483 active cell therapies in development in 2020 compared to 1,011 in 2019. Cell culture is used in the development, manufacture, and commercialization of cell therapies and holds the potential to revolutionize the healthcare industry for the treatment of various diseases. Hence, a surge in the demand for cell therapy aids in the growth of the cell culture market.

The lack of skilled professionals is expected to hinder the cell culture market’s growth. The consequence of having unskilled workers can also be detrimental to the bottom line of a company, as even a small batch error can cost an organization millions of dollars. The regulatory agency that issues the facility's license requires an annual report that includes all failed batches, and if the failure rate is more than 5%, the plant may be at risk of losing the ability to sell its drug. Furthermore, according to a skills survey by the Cell and Gene Therapy Catapult (CGTC) in 2019, UK cell and gene therapy firms are worried about the shortage of skilled manufacturing staff for the expansion of their business. The lack of talent is expected to adversely impact the growth of the cell and gene therapy industry, thereby restraining the growth of the cell culture market.

The development of products for 3D cell culture by the companies operating in the cell culture market is gaining significant popularity. A 3D cell culture is an artificially created environment in which biological cells are permitted to grow or interact with their surroundings in all three dimensions, similar to how they would in a living organism. For instance, in July 2020, Rigenerand, an Italian company engaged in the production of innovative cell-based technology products for regenerative medicine and oncology, has launched a 3D bioreactor called VITVO handheld bioreactor to offer increased usability, sizing, closed system, and flexibility for 3D cell culture technologies. Similarly, Jellagen, a UK-based marine biotechnology company, launched JellaGel, a jellyfish collagen hydrogel, suitable for 3D cell culture and tissue engineering.

In March 2020, Danaher, a US-based Fortune 500 science and technology company, has acquired the biopharma business of General Electric Life Sciences for an amount of $21.4 billion. As a part of Danaher, the company is to be called Cytiva and will be a standalone operating company within Danaher's Life Sciences segment. GE Biopharma’s offerings included cell culture media, single-use technologies, process chromatography hardware & consumables, development instrumentation and consumables, and service.

Major players in the cell culture market are Thermo Fisher Scientific Inc., Corning, Inc., Becton, Dickinson and Company, Eppendorf AG, Merck KGAA, Lonza Group AG, Sartorius AG, Promocell GmbH, Danaher, Sartorius.

The regions covered in the cell culture market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cell culture market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global cell culture market is segmented -

1) By Type: Primary Cell Culture, Secondary Cell Culture, Cell Line

2) By Media: Natural, Artificial

3) By Applications: Stem Cell Technologies, Cancer Research, Biopharmaceutical, Tissue Engineering & Regenerative Medicine, Others

The cell culture consumables and equipment global market consists of sales of cell culture consumables, equipment and related service. Cell culture consumables include sera, media, reagents, and equipment such as bioreactors, cell counters, filtration systems, centrifuges, and incubators. The services includes only installation and maintenance services offered by equipment manufacturers. Cell culture consumables and equipment are designed to aid scientist in growing new cells in the culture media for drug development, tissue culture, and engineering, gene therapy, vaccine production and toxicity testing.

The cell culture consumables and equipment market covered in this report is segmented by product into consumables, instruments. The cell culture consumables and equipment global market is also segmented by end user into industrial, biotechnology, agriculture, others; by application into vaccination, toxicity testing, cancer research, drug screening and development, recombinant products, stem cell technology, regenerative medicine, others; by consumables into media, sera, reagents; by instruments into cell culture vessels, bioreactors, biosafety cabinets, carbon dioxide incubators, centrifuges.

The global cell culture consumables and equipment market is expected to grow from $8.55 billion in 2020 to $9.46 billion in 2021 at a compound annual growth rate (CAGR) of 10.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cell culture consumables and equipment global market is expected to reach $13.49 billion in 2025 at a CAGR of 9.3%.

Increase in prevalence of chronic diseases is driving the growth of cell culture consumables and equipment market. Chronic diseases such as cancer, diabetes, heart diseases, obesity and hypertension are growing rapidly. A few chronic diseases are caused due to loss or damage of certain type of cells. Such diseases can be cured by replacing the destroyed cells with new ones that are produced by pluripotent stem cells, using cell culture consumables and equipment. So, with the rising incidence of chronic diseases, there is an increased need for such equipment that can produce new cells outside the natural environment, thus driving the growth for this market. For example, according to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020.

Contamination of cell culture is the most prominent factor restricting the growth of cell culture consumables and equipment market. Contaminated culture is the presence of non-living substances or unwanted foreign microorganisms that have undesirable effects on the cell culture. Using contaminated culture cells has a number of negative consequences on the users and thus hampers the growth of this market. For example, an article published on MedCrave, stated that Mycloplasma is one of the most common and difficult to detect contaminants. The article also highlighted the results of a study on fibroblasts and keratinocyte cell lines that showed 32.35% of contamination, out of which 17.65% were mycoplasma contaminated cultures, followed by fungal (8.82%) and bacterial (5.88%) contaminants. Hence, the high risk associated with cell culture techniques pose a threat to the growth of cell culture consumables and equipment market.

Companies in cell culture consumables and equipment are investing more in 3D cell culture for its new and advantageous features. 3D cell culture may be defined as the culture of living cells within micro-assembled devices and supports that present a three dimensional structure and are used to replicate a tissue or an organ in an artificial environment by allowing the cells to interact with the surroundings in all three directions. 3D cell cultures are more relevant with higher degree of structural complexity and maintains the steady state for more time as compared to 2D cell cultures. Visikol launched OpenLiver 3D cell culture models in January 2019 to enter into 3D cell culture technology.

FDA regulates the cell culture consumables and equipment in the U.S. Under title 21, Sec 864.2240. For cell and tissue culture equipment FDA states that if the equipment is not labelled or mentioned as sterile, they would be removed from good manufacturing practice of the quality system. Additionally, each manufacturing unit should maintain procedures to receive, review, and evaluate complaints. These procedures require consistency and punctuality along with the documentation of the receipts. Therefore, these regulatory standards improves the safety and efficacy of instruments and consumables used during cell culture processes.

Thermo Fisher acquired Brammer Bio for $1.7 billion in March 2019. Brammer Bio is a contract development and manufacturing organization (CDMO) for cell and gene treatment centered biotechs. This transaction will strengthen Thermo Fisher to grow faster and expand cell culture market in other countries. Brammer Bio is formed through the merger of Florida Biologix and Brammer Biopharmaceuticals in March 2016 and is headquartered in Cambridge, MA.

Major players in the cell culture consumables and equipment global market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare and Merck KGaA.

The regions covered in the cell culture consumables and equipment global market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cell culture consumables and equipment global market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global cell culture consumables and equipment market is segmented -

1) By Product: Consumables, Instruments

2) By End User: Industrial, Biotechnology, Agriculture, Others

3) By Application: Vaccination, Toxicity Testing, Cancer Research, Drug Screening and Development, Recombinant Products, Stem Cell Technology, Regenerative Medicine, Others

4) By Consumables: Media, Sera, Reagents

5) By Instruments: Cell Culture Vessels, Bioreactors, Biosafety Cabinets, Carbon Dioxide Incubators, Centrifuges

The stem cell/cord blood banking global market consists of sales of stem cell/cord blood banking services and related goods. Cord stem cells are referred to as regenerative medicines which help in regeneration of tissues or cells in the body. Stem cells therapy is designed to aid the physician in performing medical treatment of different types of cancers, neurodegenerative diseases, graft-versus-host disease and heart diseases. The main cell types of stem cell/cord blood banking are adult stem cells, umbilical cord blood stem cells, and embryonic stem cells. Adult stem cells are a rare population of cells found in the body for the majority of postnatal life that give rise to a limited number of mature cell types that form the tissue in which they dwell. The different types of services include collection, processing, analysis, storage and involves various types of banks such as private banks, public banks. The different applications include leukemia, anemia, thalassemia, autism, cerebral palsy, diabetes and others. The global stem cell/cord blood banking market size is expected to grow from $9.38 billion in 2021 to $10.23 billion in 2022 at a compound annual growth rate (CAGR) of 9%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The stem cell/cord blood banking market is expected to reach $14.44 billion in 2026 at a CAGR of 9%. Increasing number of cancer patients is a major driver for the stem cell /cord blood banking market. Cancer diseases such as leukemia and multiple myeloma can be treated by stem cell transplant. In stem cell transplant, treatment can be either done by autologous transplant in which the stem cells come from the same person who gets the transplant or by allogeneic transplant in which means the stem cells come from a matched related or unrelated donor. By using stem cells in the treatment of cancer, the blood forming stem cells which are damaged during chemotherapy can be restored. According to the American Cancer Society, in 2019, around 606,880 deaths were caused in USA due to prevalence of the cancer which can be treated by transplanting the stem cells. Lack of awareness especially among pregnant women is a major restraint for the stem cell/cord blood banking market. This is mainly because a majority of pregnant women are unaware of the functioning of the public cord blood banks. Hence, this option is not fully explored despite the advantages of stem cell transplantation in treating cancer. For example, according to the survey by International Journal of Reproduction, Contraception, Obstetrics and Gynecology (IJRCOG), only 45% of pregnant women were informed about the uses of umbilical cord blood during pregnancy, just 5% were aware about the cost of the procedure and less than 1% were aware about the availability of cord blood banking. Pairing of cord blood and tissue storage with genetic testing services is an emerging trend in the stem cell and cord blood banking market. Such pairing is possible and efficient because of its complimentary services to the existing clients, thereby helping in expanding their product portfolio. For example, genetic testing company Natera launched the Evercord cord blood and tissue storage service that enables expectant parents to collect, store and potentially retrieve their newborn's cord blood and tissue for therapeutic use in transplantation and regenerative medicine applications. The US Food and Drug Administration (FDA) outlines guidance related to stem cells/cord blood banking in accordance with section 212 of the Small Business Regulatory Enforcement Fairness Act (Public Law 104-121). As per this act, stem cells sourced from cord blood for unrelated allogeneic use are regulated by the FDA, and, in order to distribute these products, distributors need to get a license from the FDA. These licenses are provided by the FDA after reviewing the manufacturing and the storage conditions. In this regard, the American Association of Blood Banks (AABB) and other regulatory agencies also work with the FDA. Hence, the regulatory scenario related to the stem cells/cord blood banking market is expected to keep a check on companies involved in this market. In September 2019, CBR, a US-based Cryobank Life Sciences company acquired Natera's Evercord cord blood and tissue banking business for an undisclosed amount. This acquisition will allow Natera to focus squarely on its core genetic testing business in reproductive health, oncology and organ transplantation. Natera Inc is a genetic testing company that operates a CLIA-certified laboratory in San Carlos, California. Major players in the stem cell/cord blood banking market are AMAG Pharmaceuticals, Cordlife, Cryo-Cell International, Esperite, Americord Registry LLC, China Cord Blood Corporation, Cordlife Group Limited, CordVida, ESPERITE N.V. and Cryo Stemcell. The regions covered in the stem cell/cord blood banking market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the stem cell/cord blood banking market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global stem cell/cord blood banking market is segmented - 1) By Cell Type: Adult Stem Cells, Umbilical Cord Blood Stem Cells, Embryonic Stem Cells 2) By Service: Collection, Processing, Analysis, Storage 3) By Bank Type: Public, Private 4) By Application: Leukemia, Anemia, Thalassemia, Autism, Cerebral Palsy, Diabetes, Others

The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Induced pluripotent stem cells are the regenerated form of stem cells, which are produced from an existing adult cell, such as from hepatocytes, fibroblasts, keratinocytes and neurons. The main derived cell types of induced pluripotent cells are hepatocytes, fibroblasts, keratinocytes, amniotic cells and others. Hepatocytes are the liver's primary functional cells, performing a staggering array of metabolic, endocrine, and secretory tasks. The various application includes academic research, drug development and discovery, toxicity screening, and regenerative medicine and are used in several sectors such as hospitals, research laboratories. The global induced pluripotent stem cell (iPSC) market size is expected to grow from $ 2431.2 million in 2021 to $ 2640.80 million in 2022 at a compound annual growth rate (CAGR) of 8.6%. The growth in the iPSC market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The induced pluripotent stem cell market is expected to reach $ 3571.48 million in 2026 at a CAGR of 7.8%. Increase in the prevalence of chronic disorders is one of the major factors that is driving the growth of the induced pluripotent stem cell market. Chronic disorders like heart disease, cancer, stroke, diabetes can be treated with induced pluripotent stem cells. Induced pluripotent stem cells are taken from any tissues from a child or an adult and are genetically modified to behave like embryonic stem cells. According to the report published by Partnership to Fight Chronic Disorder (PFCD), it was found that out of 133 million Americans, 45% of the population had at least one chronic disorder. Moreover, it was estimated that 7 out of 10 deaths in the USA, which is approximately 1.7 million, are due to chronic disorders and these deaths can be controlled by induced pluripotent stem cell treatment. This rise in incidences of chronic diseases is driving the demand for induced pluripotent stem cell treatment. The potential risk of tumour is one of the major restraints on the growth of Induced pluripotent stem cell market. As per a scientific research, it was found that there might be a chance of getting cancer from the treatment and people are unwilling to take treatment through Induced pluripotent stem cell therapy. According to the report by American Association for cancer research, in most of the cases while doing the experiment it was found that the occurrence of the tumours was prevalent after a short period of time. This risk of developing a tumour due to Induced pluripotent stem cell therapy is limiting the number of patients opting for this treatment, thereby restraining the growth of the market. Companies in the induced pluripotent stem cell market are looking for opportunities for strategic partnerships and collaborations that will help these companies to enter into new geographies and to expand product portfolios. For example, in November 2019, Notch Therapeutics and Allogene Therapeutics announced a partnership and licencing contract to research and develop induced pluripotent stem cell (iPSC) AlloCAR treatment goods for early use of leukaemia, multiple myeloma and non-Hodgkin lymphoma. Another Example is in January 2019, the New York Stem Cell Foundation (NYSCF) Research Institute made a strategic partnership with Ngene Therapeutics Inc. (Ngene) for the treatment of new diseases that will hold the human stem cell research and techniques like novel gene editing which means replacement of DNA at a specific cell. National Institute of Health (NIH), a part of Department of Health and Human Services, regulates the market for induced pluripotent stem cell (iPSC) in the US. If a company is using, making or planning to acquire iPSCs, they are required to provide some information. For instance, a complete and signed copy of the IPSC checklist must be submitted. Any acquisitions in the IPSC’s must obtain approval from the Institutional Review Board (IRB), the signed approval documents must be attached to the checklist. If the IPSC lines are purchased from an outside or commercial source these agreement documents must also be attested by the IRB and attached. The IPSC’s must be generated by the Intramural Research Program (IRP) under a signed contract before they can be used for any further experimentation. In August 2019, Bayer, a Germany based pharmaceutical and life sciences company acquired BlueRock Therapeutics LP for $600 million. Through the deal, Bayer would own full rights to BlueRock’s CELL+GENE™ platform, which is designed to create stable master cell banks capable of virtually unlimited expansion and differentiation into any cell type in the body, using proprietary bioprocessing and manufacturing techniques. BlueRock Therapeutics LP is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. Major players in the induced pluripotent stem cell (iPSC) market are Thermo Fisher Scientific Inc., FUJIFILM Holdings Corporation (Cellular Dynamics), Takara Bio Inc., Astellas Pharma Inc., Fate Therapeutics, ViaCyte, StemCells, Japan Tissue Engineering Co. Ltd, Fate Therapeutics and Japan Tissue Engineering Co. The regions covered in the induced pluripotent stem cell (iPSC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the induced pluripotent stem cell (iPSC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global induced pluripotent stem cell market is segmented - 1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Others 2) By Application: Academic Research, Drug Development and Discovery, Toxicity Screening, Regenerative Medicine 3) By End-User: Hospitals, Research Laboratories

The cell based assays market consists of sales of cell based assays. Cell-based assays are analytical tools that are designed to study a mechanism or process of cellular function. Companies developing cell based assays provide consumables such as reagents, assays kits and microplates as well as instruments, services and software. This report includes sales of reagents, cell lines, microplates, microplate, assay kits, probes and labels, and others. The main product and services of cell based assays are consumables, instruments, services, and software. Consumables are products that are used up or depleted throughout their use. The various instruments used are microplates, microplate readers, high throughput screening, and liquid handling systems and different consumables include reagents and media, cells and cell lines, probes and labels. The several technology types of cell based assays are automated handling, flow cytometry, label-free detection, high-throughput screening, others and are applied for drug discovery, basic research, ADME studies, predictive toxicology, others. The different end users include pharmaceutical and biotechnology companies, academic and government research institutes, Contract Research Organizations (CRO) and others The global cell based assays market size is expected to grow from $20.73 billion in 2021 to $22.58 billion in 2022 at a compound annual growth rate (CAGR) of 9%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cell based assays market is expected to reach $31.87 billion in 2026 at a CAGR of 9%. Research with cell based arrays is increasing with evolution and there is a definite need to move to more predictive cellular models for drug discovery in order to control the last-stage drug failures. The pharmaceutical industries’ need to efficiently commercialize drugs in order to overcome expensive failures in the last stages is a driving force in cell-based assay innovation. Failure of Investigational New Drug (IND) Phase III clinical trials results in a loss of several hundred million dollars to that company. For instance, according to report by Sigma, the return on investment for pharmaceutical companies could drop to 5% considering the current level of late-stage failures, and is an unacceptable level for most companies. Major improvements to high-content systems and data analysis from the cell based assays enable scientists to extract a more information about the cellular response and help take informed decisions during drug discovery, and further driving the market for cell based arrays. High cost of instruments is the major factor restraining the global cell based assays market. High price of the instrumentation will reduce the return on investments (ROI) owing to low adaptation. For example, Biotek developed HCA (High Content Analysis) instruments and are expensive and reserved for industrial end-users or core labs which have sufficient capital budgets. This restricts the low budgeted end-users to use cell based assays to its full potential, thereby hampering the growth of the market. Researchers are inclining towards early phase predictive toxicity testing that prevent late-stage drug failures. Predictive cell toxicity assays are being scaled up to increase screening of compounds in the early phases of drug development, reducing the cost of failure. For instance, Creative Bioarray, a biotech company provides a range of in vitro toxicity services to check drug-induced toxicities that save time and cost by reducing the chance of failure in earlier stage. These advances will make clinical testing easy and reduce the cost of operation. In April 2019, PerkinElmer, a global corporation for diagnostics, life science research, food, environmental and industrial testing acquired Cisbio Bioassays for an undisclosed amount. The acquisition expands PerkinElmer's R&D capability in cell based assay, and customer base in key growth geographies including the Americas, Europe, and China in order to expand its market reach for reagents. Cisbio Bioassays is a custom assay service provider based in Codolet, France and was founded in 1974. Major players in the cell based assays market are Thermo Fisher, Danaher, Becton, Dickinson and Company, GE Healthcare, Merck, Perkinelmer, Promega, Lonza, Charles River Laboratories and Cell Signaling Technology. The regions covered in the cell based assays market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell based assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global cell based assays market is segmented - 1) By Product and Service: Consumables, Instruments, Services, Software  2) By Application: Drug Discovery, Basic Research, Adme Studies, Predictive Toxicology, Others 3) By End User: Pharmaceutical and Biotechnology Companies, Academic and Government Research Institutes, Contract Research Organizations (CRO), Other End Users 4) By Technology: Automated Handling, Flow Cytometry, Label-Free Detection, High-Throughput Screening, Others 5) By Consumables: Reagents and Media, Cells and Cell Lines, Probes and Labels 6) By Instruments: Microplates, Microplate Readers, High Throughput Screening, Liquid Handling Systems

The cell therapy market consists of sales of cell therapy and related services. Cell therapy (CT) helps repair or replace damaged tissues and cells. A variety of cells are used for the treatment of diseases includes skeletal muscle stem cells, hematopoietic (blood-forming) stem cells (HSC), lymphocytes, mesenchymal stem cells, pancreatic islet cells, and dendritic cells.

The global cell therapy market is expected to grow from $7.2 billion in 2020 to $7.82 billion in 2021 at a compound annual growth rate (CAGR) of 8.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $12.06 billion in 2025 at a CAGR of 11%.

The rising prevalence of chronic diseases contributed to the growth of the cell therapy market. According to the US Centers for Disease Control and Prevention (CDC), chronic disease is a condition that lasts for one year or more and requires medical attention or limits daily activities or both and includes heart disease, cancer, diabetes, and Parkinson’s disease. Stem cells can benefit the patients suffering from spinal cord injuries, type 1 diabetes, Parkinson’s disease (PD), heart disease, cancer, and osteoarthritis. According to Cancer Research UK, in 2018, 17 million cancer cases were added to the existing list, and according to the International Diabetes Federation, in 2019, 463 million were living with diabetes. According to the Parkinson’s Foundation, every year, 60,000 Americans are diagnosed with PD, and more than 10 million people are living with PD worldwide. The growing prevalence of chronic diseases increased the demand for cell therapies and contributed to the growth of the market.

The high cost of cell therapy hindered the growth of the cell therapy market. Cell therapies have become a common choice of treatment in recent years as people are looking for the newest treatment options. Although there is a huge increase in demand for cell therapies, they are still very costly to try. Basic joint injections can cost about $1,000 and, based on the condition, more specialized procedures can cost up to $ 100,000. In 2020, the average cost of stem cell therapy can range from $4000 - $8,000 in the USA. Therefore, the high cost of cell therapy restraints the growth of the cell therapy market.

Key players in the market are strategically partnering and collaborating to expand the product portfolio and geographical presence of the company. For instance, in April 2018, Eli Lilly, an American pharmaceutical company entered into a collaboration agreement with Sigilon Therapeutics, a biopharmaceutical company that focused on the discovery and development of living therapeutics to develop cell therapies for type 1 diabetes treatment by using the Afibromer technology platform. Similarly, in September 2018, CRISPR Therapeutics, a biotechnological company that develops transformative medicine using a gene-editing platform for serious diseases, and ViaCyte, a California-based regenerative medicine company, collaborated on the discovery, development, and commercialization of allogeneic stem cell therapy for diabetes treatment.

In August 2019, Bayer AG, a Germany-based pharmaceutical and life sciences company, acquired BlueRock Therapeutics, an engineered cell therapy company, for $1 billion. Through this transaction, Bayer AG will acquire complete BlueRock Therapeutics’ CELL+GENE platform, including a broad intellectual property portfolio and associated technology platform including proprietary iPSC technology, gene engineering, and cell differentiation capabilities. BlueRock Therapeutics is a US-based biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology, and immunology, using a proprietary induced pluripotent stem cell (iPSC) platform.

The major players covered in the global cell therapy market are Fibrocell Science Inc., JCR Pharmaceuticals Co. Ltd., PHARMICELL Co. Ltd., Osiris Therapeutics Inc., MEDIPOST, Vericel Corporation, Anterogen Co. Ltd., Kolon TissueGene Inc., Stemedica Cell Technologies Inc., AlloCure, Arteriocyte Medical Systems, Athersys Inc., Baxter Healthcare Corporation, Bone Therapeutics, Celgene Corporation, Cell Medica, Cellerant Therapeutics, Forticell Bioscience, Mesoblast Ltd, AlloSource, Holostem Terapie Avanzate S.r.l, Pharmicell Co. Ltd, TiGenix (Takeda Pharmaceuticals), Stempeutics Research Pvt. Ltd., Nipro Corp, Tego Science, Corestem Inc., Forticell Bioscience, Cellerant Therapeutics, Cells for Cells.

The countries covered in the global cell therapy market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The regions covered in the global cell therapy market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The global cell therapy market is segmented -

1) By Technique: Stem Cell Therapy, Cell Vaccine, Adoptive Cell Transfer (ACT), Fibroblast Cell Therapy, Chondrocyte Cell Therapy

2) By Therapy Type: Allogeneic Therapies, Autologous Therapies

3) By Application: Oncology, Cardiovascular Disease (CVD), Orthopedic, Wound Healing, Others

The 3D cell culture technologies market consists of sales of 3D cell culture technologies and related services. Some of the 3D cell culture technologies include microfluidics, hydrogels scaffolds, scaffold-free 3D cell culture techniques, spheroids, cube, spherical droplet, stacked plate, magnetic bead, organ-on-chips and other technologies. The 3D cell culture technologies market does not include sales of cell culture consumables and instruments. The main types of 3D cell culture technologies are scaffold-based, scaffold-free, and 3D bioreactors. The 3D bioreactors are small plastic cylinder chambers designed specifically for growing cells in three dimensions. The various scaffold-based technologies include hydrogels, polymeric scaffolds, micropatterned surface microplates and the different scaffold-free technologies are hanging drop microplates, spheroid microplates, microfluidic 3d cell culture, magnetic levitation and 3D bioprinting. The technologies are applied for cancer research, stem cell research, drug discovery, and regenerative medicine that are used by research laboratories and institutes, biotechnology and pharmaceutical companies, hospitals and diagnostic centers, and other end users. The global 3D cell culture technologies market size is expected to grow from $2.03 billion in 2021 to $2.39 billion in 2022 at a compound annual growth rate (CAGR) of 18.0%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The 3D cell culture technologies market is expected to reach $4.71 billion in 2026 at a CAGR of 18.5%. The increasing requirement for organ transplantation is driving the 3D Cell Culture Technologies Market. 3D cell culture helps in forming a three-dimensional structure which further helps in mimicking the tissue or organ and therefore helps in organ transplantation. 3D cell structures are capable of tissue and organ regeneration as well as providing the provision for drug toxicology screening. According to the U.S. government information on organ donation and transplantation, 39,718 transplants were performed in 2019 and above 109,000 people are waiting for the transplant as of September 2020. The possibility of contaminating the cells is restricting the 3D Cell Culture technologies market. Contamination of the cell culture refers to the presence of bacteria, moulds, yeasts, viruses, and mycoplasma that can adversely affect the cell culture. Contamination usually occurs when the cells are mishandled or due to the lack of adequate care, as a result the process of regeneration may get affected. According to a study conducted by Yale and Tuff's university, it was found that 3D cultures are more complex than 2D cell cultures and they require a more controlled cellular environment in order to mimic structures for tissue or organ transplants. Therefore, probability of cell culture contamination is relatively higher in 3D cell cultures. Implementing the latest technology is the latest trend in the 3D Cell culture market. For example, various companies have adopted one such advancement into the market for 3D cell culture, this is the use of the vivo/vitro environment. Cell expansion and interactions under 2D are not appropriate in vitro models but when compared with 3D cell culture technique, it offers a better cell culture environment. The Vitro environment enables researchers or doctors to conduct the procedure in a controlled environment outside the organism. This procedure is gaining importance as it plays a vital role in monitoring the health of patients. FDA approved Biotek's 3D cell expansion system to be used as a medical device. It also approved Biotek's Polycaprolactone (PCL) which is a biodegradable polyester material that is used in many FDA approved implants and drug delivery devices. FDA regulates the cell culture technologies under title 21, sec 864.2240. FDA states that cell and tissue culture technologies should be labelled or mentioned as sterile, or else they would be removed from the good manufacturing practice of the quality system. Each technology unit should maintain procedures to receive, review, and evaluate complaints. These procedures should also include the consistent documentation of the receipts. In May 2021, CELLINK Group, a USA-based startup that designs and supplies technologies and services to enhance biology research, has acquired Visikol Corporation for $7.5 million. With this acquisition, CELLINK made an entrance into the contract research market. Visikol Corp., an American contract research services company that provides pharma and biotech industries with leading services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology. Major players in the 3D cell culture technologies market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Lonza, HiMedia Laboratories, Agilent Technologies, PromoCell GmbH, CellGenix GmbH, InvivoGen, Greiner Bio-One, Irvine Scientific, Cell Culture Company (CCC) LLC, Sera Care Life Sciences Incorporation, American Type Culture Collection, Miltenyi Biotec, AITbiotech, ESSEN, Sigma-Aldrich, Bel-Art, MilliporeSigma, Cellgenix, Sumitomo Bakelite, EMD Millipore, AffymetrixInc, VWR International, LLC, WHEATON IndustriesInc, and Sartorius AG. The regions covered in the 3D cell culture technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the 3D cell culture technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global 3D cell culture technologies market is segmented - 1) By Type: Scaffold-Based, Scaffold-Free, 3D Bioreactors 2) By End Users: Research Laboratories and Institutes, Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostic Centers, Other End Users 3) By Scaffold-Based: Hydrogels, Polymeric Scaffolds, Micropatterned Surface Microplates 4) By Scaffold-Free: Hanging Drop Microplates, Spheroid Microplates, Microfluidic 3D Cell Culture, Magnetic Levitations and 3D Bioprinting 5) By Application: Cancer Research, Stem Cell Research, Drug Discovery, Regenerative Medicine